Navigation Links
Telesta Therapeutics Inc. Announces Results of Annual General Meeting of Shareholders
Date:11/16/2015

MONTREAL, Nov. 16, 2015 /PRNewswire/ - Telesta Therapeutics Inc. (TSX: TST; PNK: BNHLF) ("Telesta" or the"Corporation") today announced the voting results from its annual general meeting of shareholders held November 12, 2015 in Montreal (the "Meeting").  The details of the meeting agenda and each of the agenda items can be found in the Corporation's proxy circular dated September 25, 2015 which can be found at www.sedar.com or on the Corporation's website at www.telestatherapeutics.com

The five nominees for the position of director of the Corporation were elected as presented in the table below.  Each of these individuals is to serve as a director of the Corporation to hold office for the ensuing year or until his or her successor is elected.

 NomineeVotes For% ForVotes Withheld% WithheldYvon Bastien

104,941,901

98.96

1,106,508

1.04Dr. Michael Berendt

105,405,397

99.39

642,958

0.61Lyne Fortin

105,915,181

99.87

133,228

0.13James Rae

104,424,859

98.85

1,618,496

1.15Warren Whitehead

104,976,695

98.99

1,067,214

1.01

 

Shareholders at the Meeting also approved the re-appointment of Telesta's auditors, Ernst & Young LLP, Chartered Accountants and re-approved: the Group Registered Retirement Savings and Employee Savings Plans, the Shareholders' Rights Plan, and the 2015 Amended and Restated Stock Option Plan.  In addition, the Advance Notice By-Law of the Corporation was confirmed, ratified and approved.

Finally, a special resolution amending the articles of the Corporation to consolidate the issued and outstanding Common Shares at a ratio of up to fifteen (15) pre-consolidation for every one (1) post-consolidation Common Share if, as and when determined by the Board of Directors over a period of one year, was confirmed, ratified and approved.

About Telesta Therapeutics Inc.

Telesta Therapeutics Inc. is a late stage therapeutics company with near term commercial potential. The Company recently submitted a Biologics License Application (BLA) with the FDA for MCNA, its drug for high risk non-muscle invasive bladder cancer, and has been granted Priority Review with a PDUFA date of February 27, 2016.  The Company's primary goal is to develop and commercialize products in the United States that advance human health and increase shareholder value. For more information, please visit www.telestatherapeutics.com

Except for historical information, this news release may contain "forward-looking statements" and "forward-looking information" within the meaning of applicable securities laws that reflect the Company's current expectation regarding future events. Forward-looking statements and information are necessarily based upon a number of estimates and assumptions that, while, considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Readers are cautioned that any such forward-looking statements and information are not guarantees and there can be no assurance that such statements and information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements and information. These forward-looking statements and information involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements and information whether as a result of new information, future events or otherwise. All written and oral forward-looking statements and information attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements.

 


'/>"/>
SOURCE Telesta Therapeutics Inc.
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Telesta Therapeutics ernennt Brian J. Groch zum Chief Commercial Officer
2. Telesta gibt Datum des FDA-Beratungsausschusses zur Diskussion des Zulassungsantrags für MCNA bekannt[1]
3. Media Alert: Lexicon To Discuss Complete Results Of Pivotal Phase 3 TELESTAR Study
4. Telesta Therapeutics schließt Privatplatzierung über 28,6 Mio. USD ab
5. Telesta Therapeutics gibt Partnerschaft für MCNA und gleichzeitige Privatplatzierung in Südkorea bekannt
6. Capricor Therapeutics Reports Third Quarter 2015 Business & Financial Highlights
7. Viking Therapeutics to Present at Upcoming Life Science Industry Events
8. Myelofibrosis Pipeline Therapeutics Reviewed for H2 2015 in New Research
9. Tobira Therapeutics Reports Third Quarter 2015 Financial Results
10. Astellas to Acquire Ocata Therapeutics
11. PTC Therapeutics Reports Third Quarter 2015 Financial Results, Provides Corporate Update and Reviews Key Findings from ACT DMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2020)... ... 2020 , ... Dignitana AB , world leader in scalp cooling innovation, ... sponsor three signature events in 2020 with Susan G. Komen®. The sponsorship extends Dignitana’s ... the Cure® and MORE THAN PINK Walk® events in key Dignitana markets throughout year. ...
(Date:2/14/2020)... ... February 14, 2020 , ... Group Health Dental , ... that conveniently offers a complete range of dental services under one roof. The midtown ... Dentist by Find Local Doctors . Find Local Doctors is a trusted online ...
(Date:2/13/2020)... (PRWEB) , ... February 13, 2020 , ... The global ... up 2.9% from the estimated value of $93.9 billion in 2010, according to a ... , “Growth in this market is driven by an aging population ...
Breaking Medicine Technology:
(Date:2/21/2020)... ... 2020 , ... Used for years as a natural facial ... a viable replacement for invasive cosmetic surgery, such as breast augmentation. According to ... market leader for the expected robust growth of autologous fat grafting procedures. At ...
(Date:2/20/2020)... (PRWEB) , ... February 20, 2020 , ... R3 Stem ... Program was able to complete 70 complimentary stem cell procedures on military ... regenerative therapies at no cost. , At the R3 Stem Cell Training Course for ...
(Date:2/19/2020)... ... February 19, 2020 , ... ... application deadline for its new Lifestyle Medicine Residency Curriculum (LMRC). The curriculum is ... into medical residency programs. Driven by resident involvement, the curriculum has included ...
(Date:2/19/2020)... ... 19, 2020 , ... Nvision Biomedical Technologies , a ... for lower extremities at the American College of Foot and Ankle Surgeons Annual ... Ti Stand-Alone Osteotomy Wedge Fixation System will lead Nvision's innovative showcase. The Trigon ...
(Date:2/15/2020)... (PRWEB) , ... February 14, 2020 , ... ... cleaning products, partnered with Baptist Easley Hospital , a member of Prisma ... patient environments. With PCPLUS, the world-class hospital was able to cut its monthly ...
Breaking Medicine News(10 mins):